Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 15-16/2013

01.08.2013 | main topic

Malignant melanoma: epidemiologic aspects, diagnostic and therapeutic approach

verfasst von: Michael Tronnier, MD, Kristina Semkova, MD, PhD, Uwe Wollina, MD, Georgi Tchernev, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 15-16/2013

Einloggen, um Zugang zu erhalten

Summary

In faired skinned population the incidence of melanoma is rapidly increasing. Beside environmental factors (UV-exposure) certainly other reasons for the observed “melanoma epidemic” have to be discussed. For diagnostic procedure classical histopathology is accompanied by immunohistochemistry and more recently molecular techniques. For therapy new modalities are available which—after many years of frustrating search for new drugs—are now able to prolong both disease/progression free and overall survival.
Literatur
1.
Zurück zum Zitat Erickson C, Driscoll MS. Melanoma epidemic: facts and controversies. Clin Dermatol. 2010;28:281–5.PubMedCrossRef Erickson C, Driscoll MS. Melanoma epidemic: facts and controversies. Clin Dermatol. 2010;28:281–5.PubMedCrossRef
2.
Zurück zum Zitat Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129:1666–74.PubMedCrossRef Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129:1666–74.PubMedCrossRef
4.
Zurück zum Zitat Volkovova K, Bilanicova D, Bartonova A, et al. Associations between environmental factors and incidence of cutaneous melanoma. Rev. Environ Health. 2012;11:1–12.CrossRef Volkovova K, Bilanicova D, Bartonova A, et al. Associations between environmental factors and incidence of cutaneous melanoma. Rev. Environ Health. 2012;11:1–12.CrossRef
5.
Zurück zum Zitat Erdmann F, Lortet-Tieulent J, Schüz J, et al. International trends in the incidence of malignant melanoma. 1953–2008—are recent generations at higher or lower risk? Int J Cancer. 2012;132:385–400.PubMedCrossRef Erdmann F, Lortet-Tieulent J, Schüz J, et al. International trends in the incidence of malignant melanoma. 1953–2008—are recent generations at higher or lower risk? Int J Cancer. 2012;132:385–400.PubMedCrossRef
6.
Zurück zum Zitat Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systemic review of epidemiologic studies. Cancer Causes Control. 2001;12:69–82.PubMedCrossRef Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systemic review of epidemiologic studies. Cancer Causes Control. 2001;12:69–82.PubMedCrossRef
7.
Zurück zum Zitat Weyers W. The “epidemic” of melanoma between under- and overdiagnosis. J Cutan Pathol. 2012;29:9–16.CrossRef Weyers W. The “epidemic” of melanoma between under- and overdiagnosis. J Cutan Pathol. 2012;29:9–16.CrossRef
8.
Zurück zum Zitat Choudhury K, Volkmer B, Greinert R, et al. Effectiveness of skin cancer screening programs. Br J Dermatol. 2012;167:94–8.PubMedCrossRef Choudhury K, Volkmer B, Greinert R, et al. Effectiveness of skin cancer screening programs. Br J Dermatol. 2012;167:94–8.PubMedCrossRef
9.
Zurück zum Zitat Katalinic A, Waldmann A, Weinstock MA, et al. Does skin cancer screening save lives? Cancer. 2012;118:5395–402.PubMedCrossRef Katalinic A, Waldmann A, Weinstock MA, et al. Does skin cancer screening save lives? Cancer. 2012;118:5395–402.PubMedCrossRef
10.
Zurück zum Zitat Andersen LK, Hercogová J, Wollina U, et al. Climate change and skin disease: a review of the English-language literature. Int J Dermatol. 2012;51:656–61.PubMedCrossRef Andersen LK, Hercogová J, Wollina U, et al. Climate change and skin disease: a review of the English-language literature. Int J Dermatol. 2012;51:656–61.PubMedCrossRef
11.
Zurück zum Zitat Zalaudek I, Docimo G, Argenziano G. Using dermatosopic criteria and patient-related factors for the management of pigmented melanocytic nevi. Arch Dermatol. 2009;145:816–26.PubMedCrossRef Zalaudek I, Docimo G, Argenziano G. Using dermatosopic criteria and patient-related factors for the management of pigmented melanocytic nevi. Arch Dermatol. 2009;145:816–26.PubMedCrossRef
12.
Zurück zum Zitat Wollina U, Burroni M, Torricelli R, et al. Digital dermoscopy in clinical practice: a three-center analysis. Skin Res Technol. 2007;13:133–42.PubMedCrossRef Wollina U, Burroni M, Torricelli R, et al. Digital dermoscopy in clinical practice: a three-center analysis. Skin Res Technol. 2007;13:133–42.PubMedCrossRef
13.
Zurück zum Zitat Herman C. Emerging technologies for the detection of melanoma: achieving better outcomes. Clin Cosmet Investig Dermatol. 2012;5:195–212.PubMedCrossRef Herman C. Emerging technologies for the detection of melanoma: achieving better outcomes. Clin Cosmet Investig Dermatol. 2012;5:195–212.PubMedCrossRef
14.
Zurück zum Zitat Ackerman AB, Cerroni L, Kerl H. Pitfalls in the histopathologic diagnosis of malignant melanoma. Philadelphia: Lea & Febiger; 1994. Ackerman AB, Cerroni L, Kerl H. Pitfalls in the histopathologic diagnosis of malignant melanoma. Philadelphia: Lea & Febiger; 1994.
15.
Zurück zum Zitat Tronnier M. Einflussfaktoren auf die Mikromorphologie von melanozytären Naevi. JDDG. 2004;2:987–9.PubMedCrossRef Tronnier M. Einflussfaktoren auf die Mikromorphologie von melanozytären Naevi. JDDG. 2004;2:987–9.PubMedCrossRef
16.
17.
Zurück zum Zitat Cerroni L, Barnhill R, Elder D, et al. Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol. 2010;34:314–26.PubMedCrossRef Cerroni L, Barnhill R, Elder D, et al. Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol. 2010;34:314–26.PubMedCrossRef
18.
Zurück zum Zitat Gerami P, Scolger RA, Xu X, et al. Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. Am J Surg Pathol. 2013;37(5):676–84.PubMedCrossRef Gerami P, Scolger RA, Xu X, et al. Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. Am J Surg Pathol. 2013;37(5):676–84.PubMedCrossRef
19.
Zurück zum Zitat Bauer J, Bastian BC. Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther. 2006;19:40–9.PubMedCrossRef Bauer J, Bastian BC. Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther. 2006;19:40–9.PubMedCrossRef
20.
Zurück zum Zitat Pflugfelder A, Weide B, Eigentler TK, et al. Incisional biopsy and melanoma prognosis: facts and controversies. Clin Dermatol. 2010;28:316–8.PubMedCrossRef Pflugfelder A, Weide B, Eigentler TK, et al. Incisional biopsy and melanoma prognosis: facts and controversies. Clin Dermatol. 2010;28:316–8.PubMedCrossRef
21.
Zurück zum Zitat Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline—update 2012. Eur J Cancer. 2012;48:2375–90.PubMedCrossRef Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline—update 2012. Eur J Cancer. 2012;48:2375–90.PubMedCrossRef
22.
Zurück zum Zitat Iorizzo LJ 3rd, Chocron I, Lumbang W, et al. Importance of vertical pathology of debulking specimens during Mohs micrographic surgery for lentigo maligna and melanoma in-situ. Dermatol Surg. 2013;39:365–71.PubMedCrossRef Iorizzo LJ 3rd, Chocron I, Lumbang W, et al. Importance of vertical pathology of debulking specimens during Mohs micrographic surgery for lentigo maligna and melanoma in-situ. Dermatol Surg. 2013;39:365–71.PubMedCrossRef
23.
Zurück zum Zitat Beger J, Hansel G, Krönert C, et al. A 10-year analysis of primary cutaneous malignant melanoma with sentinel lymph node biopsy and long-term follow-up. Int J Dermatol. 2013;52:220–30.PubMedCrossRef Beger J, Hansel G, Krönert C, et al. A 10-year analysis of primary cutaneous malignant melanoma with sentinel lymph node biopsy and long-term follow-up. Int J Dermatol. 2013;52:220–30.PubMedCrossRef
24.
Zurück zum Zitat Davar D, Tarhini AA, Kirkwood JM. Adjuvant therapy for melanoma. Cancer J. 2012;18:192–202.PubMedCrossRef Davar D, Tarhini AA, Kirkwood JM. Adjuvant therapy for melanoma. Cancer J. 2012;18:192–202.PubMedCrossRef
25.
Zurück zum Zitat Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomized phase III trial. Lancet. 2008;372:117–26.PubMedCrossRef Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomized phase III trial. Lancet. 2008;372:117–26.PubMedCrossRef
26.
Zurück zum Zitat Powell AM, Robson AM, Russell-Jones R, et al. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol. 2009;160:994–8.PubMedCrossRef Powell AM, Robson AM, Russell-Jones R, et al. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol. 2009;160:994–8.PubMedCrossRef
27.
Zurück zum Zitat Hervieu A, Rébé C, Végran F, et al. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol. 2013;133:499–508.PubMedCrossRef Hervieu A, Rébé C, Végran F, et al. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol. 2013;133:499–508.PubMedCrossRef
28.
Zurück zum Zitat Daponte A, Signoriello S, Maiorino L, et al. Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-Α in advanced malignant melanoma. J Transl Med. 2013;13:11–38. Daponte A, Signoriello S, Maiorino L, et al. Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-Α in advanced malignant melanoma. J Transl Med. 2013;13:11–38.
29.
Zurück zum Zitat Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707–14.PubMedCrossRef Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707–14.PubMedCrossRef
30.
Zurück zum Zitat Menzies AM, Long GV, Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther. 2012;6:391–405.PubMed Menzies AM, Long GV, Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther. 2012;6:391–405.PubMed
31.
Zurück zum Zitat Salama AK, Kim KB. Trametinib (GSK1120212) in the treatment of melanoma. Expert Opin Pharmacother. 2013;14:619–27.PubMedCrossRef Salama AK, Kim KB. Trametinib (GSK1120212) in the treatment of melanoma. Expert Opin Pharmacother. 2013;14:619–27.PubMedCrossRef
32.
Zurück zum Zitat Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694–703.PubMedCrossRef Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694–703.PubMedCrossRef
33.
Zurück zum Zitat Hanaizi Z, van Zwieten-Boot B, Calvo G, et al. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Hum. Eur J Cancer. 2012;48:237–42.PubMedCrossRef Hanaizi Z, van Zwieten-Boot B, Calvo G, et al. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Hum. Eur J Cancer. 2012;48:237–42.PubMedCrossRef
34.
Zurück zum Zitat Hersh EM, O’Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs. 2011;29:489–98.PubMedCrossRef Hersh EM, O’Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs. 2011;29:489–98.PubMedCrossRef
Metadaten
Titel
Malignant melanoma: epidemiologic aspects, diagnostic and therapeutic approach
verfasst von
Michael Tronnier, MD
Kristina Semkova, MD, PhD
Uwe Wollina, MD
Georgi Tchernev, MD
Publikationsdatum
01.08.2013
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 15-16/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-013-0207-3

Weitere Artikel der Ausgabe 15-16/2013

Wiener Medizinische Wochenschrift 15-16/2013 Zur Ausgabe